An interventional study of Audit-and-feedback in Urologic Diseases and Antibacterial Drug Adverse Reaction, sponsored by Iowa City Veterans Affairs Medical Center. Completed at 3 sites in United States. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Iowa City Veterans Affairs Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Urologic Diseases with a site in United States — 15 open to participants now, 26 under way, 9 of them phase 3. Urologic Diseases · United States.
Among the 80 studies in Urologic Diseases with a site in United States, this one is the 6th largest by enrollment of the 70 interventional ones that give a count, is one of 9 that started in 2022, is one of 23 with no phase, and was the 44th registered.
221 studies on the registry are indexed under Urologic Diseases; 48 are open to participants now.
Browse Urologic Diseases studies →15 of the 80 studies in Urologic Diseases with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 21–75 · Men only
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Jade Biosciences, Inc. · Sites in United States, Australia, New Zealand and 2 more countries
Ages 18–60
Astellas Pharma Global Development, Inc. · Sites in United States, Brazil, Canada and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Urologic Diseases studies recruiting now, 24 (65%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 19 · Phase 3 16 · Phase 4 3
First in 2008; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 525 is above the median of 80 across 160 interventional studies indexed under Urologic Diseases.
Median enrollment 58 across the 70 interventional studies, 190 across the 10 observational. Of the 49 that completed or were terminated, 26 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 80 have an industry lead sponsor. The 10 most frequent:
Iowa City Veterans Affairs Medical Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Iowa City Veterans Affairs Medical Center has 1 study filed under Urologic Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Urologic Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05952999OSF Healthcare SystemAnalysis of the Virtual Acute Care at Home Experience | 2026-12-31 |
| NCT04248283UromedicaAdjustable Continence Therapy (ACT) for the Treatment of Female SUI | 2027-05-31 |
| NCT07054684Biohaven Therapeutics Ltd.Study of BHV-1400 in IgA Nephropathy | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 80 studies in Urologic Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Antimicrobial resistance is one of today''s most urgent public health problems. An important strategy to slow the spread of antimicrobial resistance is the promotion of judicious antimicrobial use. There are many opportunities to reduce unnecessary antimicrobial-prescribing, including in patients undergoing surgical procedures. The following study will specifically study opportunities to improve antimicrobial use in patients undergoing common urologic procedures at hospitals in the Veterans Health Administration (VHA).
Guidelines recommend giving antibiotics for no more than 24-hours after most urologic procedures, but the investigators have shown that the unnecessary use of post-procedural antimicrobials is common in this setting. In a national cohort of nearly 30,000 VHA patients, excessive post-procedural antimicrobials were prescribed after 37.2% of urologic procedures for a median duration of 3.0 excess days.
In this study, the investigators will evaluate whether giving regular feedback to providers at 3 VHA hospitals can reduce unnecessary antimicrobial use after urologic procedures.
Trial design: The investigators propose a before/after quasi-experimental design, which will be analyzed with an interrupted time-series analysis.
Participants: There will be 3 intervention VHA hospitals. To be eligible, a VHA hospital must perform the following 3 urologic procedures: transurethral resection of the prostate (TURP), transurethral resection of a bladder tumor (TUBRT), and ureteroscopy (URS).
Interventions: The study team will conduct an audit-and-feedback intervention focused on the unnecessary use of prolonged antimicrobial therapy after common urologic procedures.
The audit-and-feedback intervention will target the urology providers at the 3 intervention sites.
Outcomes: The primary outcome for this study will be the frequency of excessive post-procedural antimicrobial-prescribing in the 3 urologic procedures of interest. Secondary outcomes include several safety outcomes, such as late antimicrobial prescriptions, return visits, mortality, C. difficile testing and C. difficile infection.
For each site, the pretest period will be the 2-years prior to the intervention. The intervention itself will last 1-year.
Selection of sites: Intervention sites will be randomly selected from the top quartile of all sites, as ranked on the frequency of excessive post-procedural antimicrobial-prescribing. If sites refuse to participate, additional sites will be invited until 3 sites agree to be enrolled.
Statistical methods: At the conclusion of the pilot trial, a quasi-experimental interrupted time-series (ITS) analysis will be performed to assess the change in monthly antimicrobial use for the 3 intervention sites combined. The time frame for this ITS analysis will be the two-years prior to the pilot trial's initiation through the trial's 1-year intervention period for a total of 36 months.
Inclusion Criteria:
Exclusion Criteria: None
We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
Behavioral: Audit-and-feedback
We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
Percentage of Cases Who Received Excessive Post-procedural Antimicrobials
Excessive post-procedural antimicrobial use is defined as a prescription for a antimicrobial agent on post-procedural day one. For this specific outcome measure, the numerator will be the number of patients who received an excessive post-procedural antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
Time frame: Within 1 day of the urologic procedure
Excessive Post-procedural Antimicrobial Duration (Mean)
Excessive post-procedural antimicrobial duration is defined as the duration of continuous excessive post-procedural antimicrobial use, as quantified as days of therapy per National Healthcare Safety Network methodology. This outcome will be calculated for each patient who underwent a qualifying procedure and received a post-procedural antimicrobial (primary outcome).
Time frame: Within 30-days of the urologic procedure
Percentage of Cases Who Received a Late Antimicrobial Prescription
Late antimicrobial prescription is defined as the prescription of a designated antimicrobial that does not qualify as a post-procedural antimicrobial (see above) by any provider within 7-30 days of the date of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who received a late antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
Time frame: Within 30-days of the urologic procedure
Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic
Return visits: sought urgent/emergent healthcare for any indication within 30 days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a return visit for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
Time frame: Within 30-days of the urologic procedure
Percentage of Cases Who Died (Mortality)
Mortality: all-cause death within 30-days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who died for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
Time frame: Within 30-days of the urologic procedure
Percentage of Cases Who Underwent Clostridioides Difficile Testing
Clostridioides difficile testing is defined as any laboratory test ordered for C. difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who underwent C. difficile testing within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
Time frame: Within 30-days of the urologic procedure
Percentage of Cases Who Acquired Clostridioides Difficile Infection
Clostridioides difficile infection (CDI) is defined as a positive laboratory test for C.difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a positive test for C. difficile within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
Time frame: Within 30-days of the urologic procedure
| Milestone | Intervention |
|---|---|
| Started | 525 |
| Completed | 525 |
| Not completed | 0 |
Excessive post-procedural antimicrobial use is defined as a prescription for a antimicrobial agent on post-procedural day one. For this specific outcome measure, the numerator will be the number of patients who received an excessive post-procedural antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
| Participants | Intervention | Baseline Period |
|---|---|---|
| Percentage of Cases Who Received Excessive Post-procedural Antimicrobials | 216 | 644 |
Excessive post-procedural antimicrobial duration is defined as the duration of continuous excessive post-procedural antimicrobial use, as quantified as days of therapy per National Healthcare Safety Network methodology. This outcome will be calculated for each patient who underwent a qualifying procedure and received a post-procedural antimicrobial (primary outcome).
| Days of antimicrobial therapy | Intervention | Baseline |
|---|---|---|
| Excessive Post-procedural Antimicrobial Duration (Mean) | 4.1 ± 6.4 | 5.3 ± 6.4 |
Late antimicrobial prescription is defined as the prescription of a designated antimicrobial that does not qualify as a post-procedural antimicrobial (see above) by any provider within 7-30 days of the date of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who received a late antimicrobial, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
| Participants | Intervention | Baseline Period |
|---|---|---|
| Percentage of Cases Who Received a Late Antimicrobial Prescription | 83 | 169 |
Return visits: sought urgent/emergent healthcare for any indication within 30 days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a return visit for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
| Participants | Intervention | Baseline Period |
|---|---|---|
| Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic | 113 | 186 |
Mortality: all-cause death within 30-days of the patient's index urologic procedure. For this specific outcome measure, the numerator will be the number of patients who died for any reason within 30-days of the urologic procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
| Participants | Intervention | Baseline Period |
|---|---|---|
| Percentage of Cases Who Died (Mortality) | 4 | 4 |
Clostridioides difficile testing is defined as any laboratory test ordered for C. difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who underwent C. difficile testing within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
| Participants | Intervention | Baseline Period |
|---|---|---|
| Percentage of Cases Who Underwent Clostridioides Difficile Testing | 1 | 6 |
Clostridioides difficile infection (CDI) is defined as a positive laboratory test for C.difficile within 30-days of the patient's urologic procedure. For this specific outcome measure, the numerator will be the number of patients who had a positive test for C. difficile within 30-days of the procedure, and the denominator will be all patients at the site who underwent a qualifying urologic procedure.
| Participants | Intervention | Baseline Period |
|---|---|---|
| Percentage of Cases Who Acquired Clostridioides Difficile Infection | 0 | 0 |
Collected over We monitored for adverse events during the 30-day period after the qualifying procedure was performed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention | 4/525 (0.8%) | 113/525 (21.5%) | 0/525 (0%) |
| Baseline | 4/1,272 (0.3%) | 186/1,272 (14.6%) | 0/1,272 (0%) |
| Event | Intervention | Baseline |
|---|---|---|
| Emergency Department, Urgent Care Clinic, or Hospital Re-admission within 30 days of the procedureSurgical and medical procedures | 113/525 | 186/1272 |
| Age, Continuous(Years) | Intervention | Baseline | Total |
|---|---|---|---|
| Mean | 71.9 ± 10.4 | 71.6 ± 10.0 | 71.7 ± 10.2 |
| Sex: Female, Male(Participants) | Intervention | Baseline | Total |
|---|---|---|---|
| Female | 15 | 44 | 59 |
| Male | 510 | 1228 | 1738 |
| Ethnicity (NIH/OMB)(Participants) | Intervention | Baseline | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 36 | 55 |
| Not Hispanic or Latino | 455 | 1175 | 1630 |
| Unknown or Not Reported | 51 | 61 | 112 |
| Race (NIH/OMB)(Participants) | Intervention | Baseline | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 1 | 6 | 7 |
| Native Hawaiian or Other Pacific Islander | 4 | 1 | 5 |
| Black or African American | 97 | 155 | 252 |
| White | 378 | 1026 | 1404 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 44 | 82 | 126 |
| Transurethral resection of a bladder tumor(Participants) | Intervention | Baseline | Total |
|---|---|---|---|
| Count of participants | 282 | 731 | 1013 |
| Transurethral resection of prostate(Participants) | Intervention | Baseline | Total |
|---|---|---|---|
| Count of participants | 130 | 260 | 390 |
| Ureteroscopy(Participants) | Intervention | Baseline | Total |
|---|---|---|---|
| Count of participants | 113 | 281 | 394 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Jul 2023, 11 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
Of 47 non-industry interventional studies with no phase under Urologic Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's 11 months is below that.
Counting every sponsor, half of 57 studies reached it within 24 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Iowa City Veterans Affairs Medical Center